Literature DB >> 27494340

Breast adenomyoepithelioma and adenomyoepithelioma with carcinoma (malignant adenomyoepithelioma) with associated breast malignancies: A case series emphasizing histologic, radiologic, and clinical correlation.

August W Moritz1, James F Wiedenhoefer2, Amanda P Profit3, Jaishree Jagirdar3.   

Abstract

The 2012 World Health Organization (WHO) classification of breast tumors distinguishes adenomyoepitheliomas (AMEs) as benign tumors composed of a biphasic proliferation of phenotypically variable myoepithelial cells around small epithelial lined spaces. Many AMEs have demonstrated benign behavior and are often cured with excision with negative margins, but some have exhibited malignant transformation of the myoepithelial cells, ductal epithelial cells, or both. When one of the components is histologically malignant, it is termed AME with carcinoma. Due to the rarity, the literature correlating imaging, histology, and clinical outcome is limited. A retrospective review was undertaken. A review of an institutional pathology database identified 14 cases with AME or malignant AME. Most AMEs had nonspecific imaging findings and were categorized as Bi-Rads 4. Histologic features of AME did not correlate with prior or concurrent breast malignancies or any radiographic features. Clinical follow up could be obtained for all but one case (mean follow up time = 75 months). 5 cases had no known treatment post-biopsy and 5 patients received mastectomy. No recurrences were noted. 3/13 cases of benign AME had associated breast malignancies including invasive ductal adenocarcinoma and ductal carcinoma in-situ. 1 case of malignant AME had a synchronous separate malignant phyllodes tumor. Given the unclear and unpredictable propensity for malignant transformation, conservative excision with negative margins currently seems appropriate.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AME; Adenomyoepithelioma; Adenomyoepithelioma with carcinoma; Malignant adenomyoepithelioma; Malignant transformation of adenomyoepithelioma; Radiology of adenomyoepithelioma

Mesh:

Year:  2016        PMID: 27494340     DOI: 10.1016/j.breast.2016.07.018

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  13 in total

1.  Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.

Authors:  Fresia Pareja; Michael S Toss; Felipe C Geyer; Edaise M da Silva; Mahsa Vahdatinia; Ana Paula M Sebastiao; Pier Selenica; Austin Szatrowski; Marcia Edelweiss; Hannah Y Wen; Raluca Mihai; Zsuzsanna Varga; Maria P Foschini; Brian P Rubin; Ian O Ellis; Sarat Chandarlapaty; Achim A Jungbluth; Edi Brogi; Britta Weigelt; Jorge S Reis-Filho; Emad A Rakha
Journal:  Histopathology       Date:  2020-05       Impact factor: 5.087

2.  Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity.

Authors:  Paula S Ginter; Patrick J McIntire; Boaz Kurtis; Susanna Mirabelli; Samaneh Motanagh; Syed Hoda; Olivier Elemento; Sandra J Shin; Juan Miguel Mosquera
Journal:  Mod Pathol       Date:  2020-04-30       Impact factor: 7.842

3.  Clinicopathological characteristics and outcomes of malignant adenomyoepithelioma of the breast: a single institution's experience.

Authors:  Heba Mohammad Abdulla Alqudaihi; Sae Byul Lee; Byung Ho Son; Sei-Hyun Ahn; Jong Won Lee; Beom Seok Ko; Hee Jeong Kim; Il Yong Chung; Jisun Kim; Gyungyub Gong
Journal:  World J Surg Oncol       Date:  2022-04-22       Impact factor: 2.754

4.  Radiotherapy in the Multidisciplinary Management of Adenomyoepithelioma of the Breast with an Axillary Lymph Node Metastasis: A Case Report and Review of the Literature.

Authors:  Natalie Logie; Judith Hugh; K Paulson; Robert Pearcey; Karen M King
Journal:  Cureus       Date:  2017-06-21

5.  Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

Authors:  Felipe C Geyer; Anqi Li; Anastasios D Papanastasiou; Alison Smith; Pier Selenica; Kathleen A Burke; Marcia Edelweiss; Huei-Chi Wen; Salvatore Piscuoglio; Anne M Schultheis; Luciano G Martelotto; Fresia Pareja; Rahul Kumar; Alissa Brandes; Dan Fan; Thais Basili; Arnaud Da Cruz Paula; John R Lozada; Pedro Blecua; Simone Muenst; Achim A Jungbluth; Maria P Foschini; Hannah Y Wen; Edi Brogi; Juan Palazzo; Brian P Rubin; Charlotte K Y Ng; Larry Norton; Zsuzsanna Varga; Ian O Ellis; Emad A Rakha; Sarat Chandarlapaty; Britta Weigelt; Jorge S Reis-Filho
Journal:  Nat Commun       Date:  2018-05-08       Impact factor: 14.919

6.  Benign adenomyoepitelioma of the breast: Presentation of two rare cases and review of literature.

Authors:  Eva Intagliata; Santi Gangi; Claudio Trovato; Rosario Vecchio; Angela Strazzanti
Journal:  Int J Surg Case Rep       Date:  2020-01-23

Review 7.  Papillary lesions of the breast.

Authors:  Janina Kulka; Lilla Madaras; Giuseppe Floris; Sigurd F Lax
Journal:  Virchows Arch       Date:  2021-11-03       Impact factor: 4.535

8.  Malignant transformation in a Breast Adenomyoepithelioma Caused by Amplification of c-MYC: A Common pathway to Cancer in a Rare Entity.

Authors:  Christopher A Febres-Aldana; Odille Mejia-Mejia; Kritika Krishnamurthy; Thomas Mesko; Robert Poppiti
Journal:  J Breast Cancer       Date:  2019-11-08       Impact factor: 3.588

9.  Establishment and characterization of organoids from a patient with adenomyoepithelioma of the breast.

Authors:  XiangRong Luo; JianTao She; Tao Xu; Yuan Zhou; ChuanBo Xu; JianPing Jiang; TianGang Li; Huajiang Liu; Hui Shen; Bolong Yin; Bin Dai
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 10.  Adenomyoepithelioma with a human epidermal growth factor receptor 2-fluorescence in situ hybridization-confirmed ductal carcinoma in situ component: A case report and review of the literature.

Authors:  Yusuke Amano; Mio Sakaguchi-Tamba; Yumiko Sasaki; Hisashi Oshiro; Noriyoshi Fukushima; Takashi Fujita; Shinobu Masuda; Toshiro Niki
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.